Medicinal Inorganic Chemistry Group, Department of Chemistry , University of British Columbia , 2036 Main Mall , Vancouver , British Columbia V6T 1Z1 , Canada.
Center for Comparative Medicine , 4145 Wesbrook Mall , Vancouver , British Columbia V6T 1W5 , Canada.
J Am Chem Soc. 2018 Nov 14;140(45):15487-15500. doi: 10.1021/jacs.8b09964. Epub 2018 Nov 5.
Hoctox, a versatile new octadentate acyclic chelating ligand, has been investigated as an alternative to the acyclic DTPA and the macrocyclic DOTA for trivalent metal ions useful in diagnostic medical imaging or therapeutic applications (Y, In, La, Gd, Lu). The synthesis of Hoctox is straightforward in less steps and thus more economical than those of most previously reported chelators. Complex formation equilibria in the presence of Y, In, La, Gd, and Lu revealed fast chelation and high metal-sequestering capacity. Quantitative labeling with In was achieved within 15 min at room temperature at ligand concentrations as low as 10 M, exactly the properties required for the development of kit-based radiopharmaceuticals. In vitro serum stability studies and in vivo SPECT imaging confirmed excellent complex stability of [In(octox)]. Moreover, it is more lipophilic than most of the multidentate carboxylate- or picolinate-based chelators; it therefore shows more liver clearance and provides a complementary choice in the design of metal-based pharmaceuticals and in the tuning of their pharmacokinetic properties. Finally, Hoctox showed a large fluorescence enhancement upon complexation with different metals, in particular, with Y and Lu, which could be useful for non-radioactive fluorescent stability and cell studies as well as bimodal imaging. Excellent in vitro stability of [Y(octox)] against transferrin and Fe was confirmed employing this fluorescence.
Hoctox 是一种多功能的新八齿非环螯合配体,已被研究作为替代非环 DTPA 和大环 DOTA 的方案,用于诊断医学成像或治疗应用中有用的三价金属离子(Y、In、La、Gd、Lu)。与大多数先前报道的螯合剂相比,Hoctox 的合成步骤更简单、更经济。在存在 Y、In、La、Gd 和 Lu 的情况下,对配合物形成平衡的研究表明,其具有快速螯合和高金属螯合能力。在室温下,只需 15 分钟,在 10 μM 低浓度的配体条件下,即可实现与 In 的定量标记,这正是开发基于试剂盒的放射性药物所需的特性。体外血清稳定性研究和体内 SPECT 成像证实了 [In(octox)] 的出色的络合物稳定性。此外,它比大多数多齿羧酸酯或吡啶羧酸酯基螯合剂更亲脂性;因此,在设计基于金属的药物和调整其药代动力学特性方面,它提供了一个互补的选择。最后,Hoctox 与不同金属(特别是 Y 和 Lu)络合时表现出很大的荧光增强,这对于非放射性荧光稳定性和细胞研究以及双模式成像可能是有用的。通过这种荧光,确认了 [Y(octox)] 对转铁蛋白和 Fe 的优异体外稳定性。
Inorg Chem. 2019-6-18
Chem Commun (Camb). 2015-2-11
Regen Biomater. 2023-3-27
J Nanobiotechnology. 2022-5-19
RSC Adv. 2021-4-27
Pharmaceuticals (Basel). 2022-3-31